Summary
Boston Scientific Corporation (BSX) announced on December 27, 2018, the exercise of its option to acquire Millipede, Inc. This strategic move signals Boston Scientific's intent to expand its cardiovascular portfolio, specifically targeting the treatment of severe mitral regurgitation with Millipede's innovative IRIS Transcatheter Annuloplasty Ring System. This acquisition is a significant development for investors as it highlights Boston Scientific's commitment to growth through targeted M&A in high-potential medical device markets. The IRIS system addresses a significant unmet need in the treatment of heart valve disease, positioning BSX to capture a larger share of this growing therapeutic area.
Key Highlights
- 1Boston Scientific exercised its option to acquire Millipede, Inc.
- 2Millipede, Inc. has developed the IRIS Transcatheter Annuloplasty Ring System.
- 3The IRIS system is designed for the treatment of severe mitral regurgitation.
- 4This acquisition is a strategic move to bolster Boston Scientific's cardiovascular offerings.
- 5The transaction indicates a focus on expanding into high-growth medical device segments.
- 6The filing includes the press release announcing the option exercise as an exhibit.